Unknown

Dataset Information

0

BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma.


ABSTRACT: The expression of the BCL-2 family proteins, BCL-2, BAX, BCL(XL) and BAK have been determined in a panel of 12 human ovarian carcinoma cell lines encompassing a wide range in sensitivity to cisplatin. Whereas BAX, BCL(XL) and BAK levels did not correlate with sensitivity, there was a statistically significant inverse correlation (r = -0.81; P = 0.002) between growth inhibition by cisplatin and BCL-2 levels. In sublines possessing acquired resistance to various platinum-based drugs or across a panel of human ovarian carcinoma xenografts, there was no consistent pattern of BCL-2 expression. Two relatively sensitive lines (A2780 and CH1) have been stably transfected with bcl-2 and bcl(XL) respectively and two relatively resistant lines (A2780cisR and SKOV-3) stably transfected with bax. Overexpression of BCL-2 in A2780 cells led to resistance to cisplatin compared to the vector control when assayed at 48 h post-drug incubation but a significant increase in sensitivity at 96 h. Relative rates of apoptosis at 48- and 96-h post-cisplatin exposure mirrored the growth inhibition. There was no significant difference in sensitivity of the pair of lines by clonogenic assay. No significant changes in chemosensitivity to a variety of DNA-damaging or tubulin-interactive agents were observed in the remaining transfected lines. Taken together, these results suggest that, in human ovarian carcinoma cells, high BCL-2 levels (either naturally occurring or through gene transfection) confers a trend towards sensitivity not resistance to platinum drugs.

SUBMITTER: Beale PJ 

PROVIDER: S-EPMC2363292 | biostudies-other | 2000 Jan

REPOSITORIES: biostudies-other

altmetric image

Publications

BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma.

Beale P J PJ   Rogers P P   Boxall F F   Sharp S Y SY   Kelland L R LR  

British journal of cancer 20000101 2


The expression of the BCL-2 family proteins, BCL-2, BAX, BCL(XL) and BAK have been determined in a panel of 12 human ovarian carcinoma cell lines encompassing a wide range in sensitivity to cisplatin. Whereas BAX, BCL(XL) and BAK levels did not correlate with sensitivity, there was a statistically significant inverse correlation (r = -0.81; P = 0.002) between growth inhibition by cisplatin and BCL-2 levels. In sublines possessing acquired resistance to various platinum-based drugs or across a pa  ...[more]

Similar Datasets

| S-EPMC3277593 | biostudies-literature
| S-EPMC6357888 | biostudies-literature
| S-EPMC4278743 | biostudies-literature
| S-EPMC7771303 | biostudies-literature
2012-05-14 | E-GEOD-33011 | biostudies-arrayexpress
| S-EPMC3944084 | biostudies-literature
| S-EPMC3635722 | biostudies-literature
| S-EPMC4532886 | biostudies-literature
| S-EPMC2361951 | biostudies-literature
| S-EPMC2062892 | biostudies-other